Page 1123

Category : Human Longevity

May’s turn to meet Trudeau and ‘anti-Alberta’ activities; In-The-News Nov. 15 – larongeNOW

Trudeau has been seeking common ground with the Conservative, Bloc Quebecois and NDP leaders in separate sessions as he prepares to return to Parliament in December without a majority in the Commons.

Hell need the backing of at least one of those parties to get any law passed, and his first test will be to get support for his speech from the throne, laying out his general plans for governing.

The Greens elected more MPs in the October vote than theyve ever had, but remain the only party in the Commons that doesnt have the numbers to give Trudeaus Liberals a win by voting with the government.

That makes the meeting more a courtesy than a negotiation between rivals seeking to find compromises to advance their agendas.

Also this

EDMONTON An Edmonton charity that has supported philanthropy in the community since 1953says Albertasinquiry intoso-called anti-Albertan activities ispolarizing, undemocratic and unfounded.

The Muttart Foundation, which supports early childhood education and other charities, has written a letter to Steve Allan, commissioner of the Public Inquiry Into Funding of Anti-Alberta Energy Campaigns.

It says the commission is creating a climate of fear by suggesting there is a price to be paid for disagreeing with the government.

The 174-page lettersays its not unAlbertan to criticize the oil and gas industry its democratic.

It uses government statistics to show foreign sources make up a tiny fraction of the revenue to Canadian charities.

Foundation director Bob Wyatt says he just wants any recommendations from the inquiry to be founded on fact.

ICYMI (In case you missed it)

HALIFAX There is something funky at the bottom of the Bay of Fundy.

A new survey estimates more than 1.8 million pieces of garbage are strewn over the bottom of the bay, prompting concerns about potential harm to marine life.

The study publishedThursday inMarine Pollution Bulletin found an average of137 pieces of plastic litter, dumped or lost fishing gear and other garbage per square kilometre of ocean.

The researchersused underwater photography at 281 locations over the past three years toextrapolate the amount ofgarbagepresent in a bay.

Plastics, especially plastic bags, comprised slightly over half of the total, while fishing gear ranging from traps to gloves was close to 30 per cent. Other garbage including tires or metal was just over one fifth of the total waste documented.

BiologistTony Walker, assistant professor in the schoolfor resource and environmental studies at Dalhousie University, said the litter eliminates potential habitat by covering the bottom.

What we are watching in the U.S.

SANTA CLARITA, Calif. People who knew the 16-year-old boy suspected of killing two students in a burst of gunfire at a high school outside Los Angeles described him as a quiet, smart kid who they would never expect to turn violent.

One fellow junior at Saugus High School said the suspect is a Boy Scout who she relied on to study for advanced placement European history. A student in his physics class said he seemed like one of those normal kids. A next-door neighbour who grew up with him said he kept to himself but was never threatening.

The attacker shot five students, seemingly at random, and then shot himself in the head around 7:30 a.m. Thursday, his 16th birthday, authorities said. Two students died, and the gunman was gravely wounded.

Police have not publicly identified the shooter because he is a minor. The Associated Press determined his identity based on property records for his home, which police said was searched after the shooting, and interviews with three of his friends.

The boy lived with his mother in a modest home on a leafy street in Santa Clarita, a Los Angeles suburb of about 210,000 people known for good schools, safe streets and relatively affordable housing.

Police said they had yet to determine a motive and any relationship between the gunman and the victims. Authorities said they have no indication the boy was acting on behalf of any group or ideology.

What we are watching in the rest of the world

MEXICO CITY Bolivias Evo Morales called for the United Nations, and possibly Pope Francis, to mediate in the Andean nations political crisis following his ouster as president in what he called a coup detat that forced him into exile in Mexico.

In an interview Thursday in Mexico City, Morales said he is in fact still the president of Bolivia since the countrys Legislative Assembly has not yet accepted his resignation, which he presented Sunday at the urging of military leaders following weeks of protests against a re-election that his opponents called fraudulent.

Morales said he would return to Bolivia from Mexico, which has granted him political asylum, if that would contribute to his countrys pacification.

Political analyst Kathryn Ledebur of the non-profit Andean Information Network in Bolivia, who has lived in the country for nearly 30 years, said Morales could have a case.

A resignation letter has to be presented and considered, and accepted in the plenary before it goes into effect, she said. Do I think that Evo wants to return and be president I dont see that. But does he want to mess with them? Yes. He wants to keep them guessing.

Two days after arriving in Mexico, Morales said he had received information that some Bolivian army troops are planning to rebel against the officers who urged him to resign. But he gave no further specifics on how many were in on the plan, or how they would rebel.

Morales said he was surprised by the betrayal of the commander in chief of the armed forces, Williams Kaliman.

Weird and wild

SEATTLE Can old dogs teach us new tricks? Scientists are looking for 10,000 pets for the largest study of aging in canines. They hope to shed light on human longevity, too.

The project will collect a pile of pooch data: vet records, DNA samples, gut microbes and information on food and walks. Five hundred dogs will test a pill that could slow the aging process.

What we learn will potentially be good for dogs and has great potential to translate to human health, said project co-director Daniel Promislow of the University of Washington School of Medicine.

If scientists find a genetic marker for a type of cancer in dogs, for instance, that could be explored in humans.

Owners will complete periodic online surveys and take their dogs to the vet once a year, with the possibility of extra visits for certain tests. Their welfare will be monitored by a bioethicist and a panel of animal welfare advisers.

The five-year study was formallystarted Thursday at a science meeting in Austin, Texas. The National Institute on Aging is paying for the $23-million project because dogs and humans share the same environment, get the same diseases and dogs shorter lifespans allow quicker research results, said deputy director, Dr. Marie Bernard. The data collected will be available to all scientists.

On this day in 1877

The Northwest Council passed laws to conserve the bison. However, by 1880, the bison had practically disappeared from the plains of Canada, destroying the traditional way of life of First Nations and Metis living on the Prairies.

Celebritynews

TORONTO One of Louis C.K.s accusersis disputing a Canadian comedy club CEOs reasons for booking the standup superstar earlier this year.

Julia Wolov says she is infuriated by an article written byYuk Yuks founder Mark Breslin for the Canadian Jewish News that downplayssexual misconduct she and several other women faced from the disgraced comic.

Wolov, aL.A.-based comedy writer, penned a counterpoint that lists several inaccuracies in Breslins article,which claimed she and others consented to sexual behaviour that occurred more than10 yearsago.

C.K.admitted to exposing himself toseveral womenwhile in a position of powerfollowing a bombshell 2017 New York Times report involving fiveaccusers.

Wolov says she hasnt spoken about her experiences since that New York Times story, but was moved to go public this week because Breslin touted C.K.s Jewish heritage as another reason to support him. Wolov says she and three of his other accusers from the article are also Jewish.

She says she did not consent to C.K. undressing and masturbating in front of her, and to suggest otherwise is wrong.

Breslin booked C.K. for a string of sold-out shows in Toronto in October. He declined further comment but says in his article that rattling the cage of polite society is part of the job of comics, onstage and off.

This report by The Canadian Press was first publishedNov. 15,2019.

The Canadian Press

Read more:

May's turn to meet Trudeau and 'anti-Alberta' activities; In-The-News Nov. 15 - larongeNOW

Recommendation and review posted by Alexandra Lee Anderson

Longevity And Anti-Senescence Therapy Market to Witness Stellar Growth Rate in the Next 10 Years during 2023 – Crypto News Byte

Latest posts by Morgan C. (see all)

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Get Sample Copy Of The Report@https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Request For Report Discount@https://www.trendsmarketresearch.com/report/discount/11698

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

Report Analysis@https://www.trendsmarketresearch.com/report/analysis/BCC/global-longevity-and-anti-senescence-therapy-market

See the original post:

Longevity And Anti-Senescence Therapy Market to Witness Stellar Growth Rate in the Next 10 Years during 2023 - Crypto News Byte

Recommendation and review posted by Alexandra Lee Anderson

CohBar – The Pioneer In Mitochondrial Drugs – Seeking Alpha

CohBar (CWBR) is a development-stage biotech company focused on drugs based on mitochondria-based therapeutics (MBTs), an emerging class of drugs with the potential to treat a wide range of diseases associated with aging and metabolic dysfunction, including non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, cancer, atherosclerosis, cardiovascular disease, fibrosis, neurodegenerative diseases such as Alzheimer's disease, and eventually aging itself. The company has applied for over 65 patents.

The stock is down 80% from its all-time high in January 2018, yet it has moved its lead drug into human clinical trials and has several preclinical programs in progress. This is an opportunity to own a leading company in a whole new therapeutic area at less than a $100 million market capitalization.

Dr. Pinchas Cohen, M.D., is the Dean of the USC Leonard Davis School of Gerontology. He holds the William and Sylvia Kugel Dean's Chair in Gerontology and serves as the executive director of the Ethel Percy Andrus Gerontology Center. He is on the advisory board for the Milken Institute Center for the Future of Aging. He recently received the Glenn Award for Research in Biological Mechanisms of Aging for his research on aging, neurodegeneration, cancer, and diabetes with an emphasis on the emerging science of mitochondrial-derived peptides, which he discovered.

Dr. Nir Barzilai, M.D., is the Founding Director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging, and the Paul F. Glenn Center for the Biology of Human Aging Research, all at the Albert Einstein College of Medicine of Yeshiva University. He also directs the Longevity Genes Project, a genetics study of over 600 Ashkenazi Jewish families of centenarians and their children. Dr. Barzilai discovered several "longevity genes" in humans that were validated by others and appear to protect centenarians against major age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes, and dementia.

In 2007, Cohen and Barzilai formed CohBar. The company IPO'd in January 2015 and is headquartered in Menlo Park, California.

You know that every cell in your body has the double helix of DNA - the genome. What you may not know is that most cells, with the notable exception of red blood cells, also contain mitochondria. Mitochondria generate most of each cell's supply of adenosine triphosphate (ATP), used as a source of chemical energy. Without them, you would die in about 30 seconds. Cyanide poisons by inhibiting the mitochondrial enzyme cytochrome c oxidase, thereby preventing the cells of an organism from creating ATP.

Mitochondria have their own independent DNA, inherited from the mother, which can transcribe a variety of mitochondrial proteins. There can be hundreds to thousands of mitochondria in a single cell. Mitochondrial DNA (miDNA) encodes only 37 genes, including 13 proteins essential for life and energy production in a cell. Point mutations in mitochondrial DNA have been associated with a broad spectrum of diseases, including muscle weakness, cardiomyopathy, optic nerve atrophy, retinal dystrophy, impaired hearing, and type 2 diabetes. Mitochondria control cell survival, tell old and defective cells to die, signal to the rest of the body when they are stressed, and appear to be a primary cause of aging.

Mitochondrial-derived peptides discovered by Dr. Cohen in the early 2000s are a new therapeutic paradigm. They go into the bloodstream to regulate metabolism, protect cell function, or cause cell death - the underlying factors of the diseases of aging. Humanin, the first mitochondrial peptide, is present in the brain, testes, and plasma. Humanin levels are higher in families with exceptional longevity and decline with age. A September 21, 2018, paper in Nature - Scientific Reports from Dr. Cohen's laboratory is titled: "Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans."

An earlier paper in Cell Metabolism, also from Dr. Cohen's lab, is titled: "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." MOTS-c is induced by exercise. This is the target of CohBar's first drug, now in Phase 1 human clinical trials for nonalcoholic steatohepatitis and obesity. It appears to have many other potential uses.

Source: CohBar

To develop mitochondrial-based drugs, CohBar first identifies and characterizes peptides with biological activity that are encoded within the mitochondria. Then it evaluates the therapeutic potential across different disease models. It files for intellectual property protection and has over 65 provisional patent applications that cover these peptides and their analogs - both composition of matter and method of use patents. The company's strategy is to "own the space" - to own the mitochondrial genome.

Once it has identified a mitochondrial-derived peptide or MDP, it optimizes its structure for potency and drug-like properties. These optimized peptides, or Analogs, are subjected to proprietary assays and validated disease models to match the greatest therapeutic potential to medical needs and market opportunities.

CohBar then has a mitochondrial-based therapeutic, or MBT, that can enter internal preclinical development to be partnered or advanced to the clinic. Many of the steps in this process are separately patentable.

Source: CohBar

CohBar has identified MDPs in type 2 diabetes, fibrosis, cancer, and other age-related diseases. All of these are in the discovery, optimization, and preclinical stages. Its lead drug, CB4211, is a MOTS-c analog in a Phase 1a/1b trial for safety and efficacy in nonalcoholic steatohepatitis (NASH) and obesity. NASH is caused by excess free fatty acid released by lipolysis from abdominal fat that flows directly to the liver. That causes liver fat deposits, inflammation, fibrosis, cirrhosis, and eventually liver cancer. Between 12 million and 20 million US patients create a $20 billion to $40 billion market, and there are no approved therapies.

CB4211 has a novel mechanism of action - it inhibits lipolysis, which reduces fatty acid release, leading to a reduction of liver fat. The preclinical data in mice showed a significant 33% reduction in the Non-Alcoholic Fatty Liver Disease Activity Score after only three weeks, improvement in liver triglycerides and plasma ALT (alanine aminotransferase), and normalization of weight in obese animals. The Phase 1a/1b trial is scheduled to end next February, and we should see results in the summer of 2020.

CohBar has identified a new peptide for type 2 diabetes that improved glucose tolerance in diet-induced obese mice. They presented a poster at the June 2019 American Diabetes Association meeting and are optimizing its potency and drug-like qualities.

A new peptide has shown a significant reduction in tumor cell growth in cultured human tumor cells. Twenty different human tumor cell types have been screened against 20 CohBar peptides, and there is evidence of effects against a broad range of tumor types. CohBar also is exploring another new peptide analog that shows antifibrotic effects in lung cells. It has been effective in a mouse model of pulmonary fibrosis. Fibrosis is a major source of organ failure in an aging population and accounts for up to one-third of all deaths worldwide.

Mitochondria play a central role in energy production, cell signaling, and communication. Mitochondrial dysfunction may play a pivotal role in chronic diseases, providing opportunities for drugs that manage and cure the disease instead of just ameliorating the symptoms. CohBar "owns the space" with over 65 patent filings and six issued patents exclusively licensed from UCLA and the Albert Einstein College of Medicine. The company has evaluated over 100 peptides encoded in the mitochondrial DNA and their analogs for potential development into novel drugs treating a wide range of diseases.

It has an experienced drug discovery, development, and partnership team. CEO Steve Engle has over 30 years of executive experience with public biotech companies. He was the Chairman and CEO of XOMA (XOMA) and La Jolla Pharmaceuticals (LJPC). Chief Scientific Officer Ken Cundy PhD has over 30 years of drug development experience at Gilead (NASDAQ:GILD) and Sterling Winthrop.

We are paying a market capitalization of well under $100 million for a company with broad patent protection of new ways to treat and cure the diseases of aging - and perhaps aging itself. There are different approaches to the difficult task of valuing any development-stage biotech stock (See here, here, and here for three examples). Obviously, if CohBar eventually develops drugs that can slow, stop, or even reverse aging, it will be an enormously successful company.

But the most conservative way to value any biotech is to calculate the ultimate value of their drugs in clinical trials and then use a high discount rate to get a value today. In CohBar's case, taking the midpoint estimate of $30 billion for the NASH market and adding $10 billion for the obesity market gives a $40 billion total available market. There are no treatments for NASH and nothing has caught on for obesity. Once CB4211 is approved, CohBar may be valued as if it can capture half of that market. But it won't be approved for about eight years, so we have to discount an ending valuation back to today using a high discount rate to reflect regulatory uncertainty and future dilution. A high 33% discount rate would give CWBR a discounted present value of $2 billion - more than 20x its current value. That may seem outrageous at first glance, but the risk is in the drug development process, not the valuation. A successful NASH and obesity drug should make CWBR worth multiple of its current value eight years from now.

CohBar is pioneering an entirely new therapeutic approach and therefore the risks of failure in human clinical trials, either for safety or, more likely, efficacy reasons are higher than usual. It will take it eight to ten years to bring its first drug to FDA approval. We can expect the FDA to be very cautious with the first mitochondria-based drugs.

The company had $14.4 million in cash and no debt at the end of September, which will carry it into the second half of 2020. CohBar's broad patent portfolio gives it, in the words of Scott McNealy of Sun Microsystems, "insurmountable opportunities" to partner out some development programs in return for milestone payments and eventual royalties. It is actively looking for non-dilutive partnerships with larger companies, but an investor has to assume there will be more financings coming. As I tell my subscribers, the second-worst news is: "Your biotech company just raised money." The first-worst news? "Your biotech company can't raise money."

CohBar is only in a Phase 1a/b safety and efficacy trial. These days, preclinical work has gotten so good that very few drugs fail their Phase 1a human safety trial. However, it is still true that efficacy in preclinical animal studies does not always translate to efficacy in human trials. Some investors may prefer to wait for the Phase 1 efficacy results to buy the stock, even if they have to pay a higher price for a de-risked situation. If mitochondrial medicine works as well as I expect it to, CohBar will offer many profitable entry opportunities over the next several years.

Disclosure: I am/we are long CWBR. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: CWBR is one of seven $20-for-$1 biotech stocks that are current Buys in New World Investor. To see more go to newworldinvestor.com/welcome-seekingalpha-reader.

Read the original:

CohBar - The Pioneer In Mitochondrial Drugs - Seeking Alpha

Recommendation and review posted by Alexandra Lee Anderson

This Scientist Believes Aging Is Optional – Outside Magazine

The oldest-known living person is Kane Tanaka, a Japanese woman who is a mind-boggling 116 years old. But if you askDavid Sinclair, hed argue that 116 is just middle age. At least, he thinks it should be. Sinclair is one of the leading scientists in the field ofaging, and he believes that growing oldisnt a natural part of lifeits a disease that needs a cure.

Sounds crazy, right? Sinclair, a Harvard professor who made Times list of the100 most influential people in the world in 2014, will acquiesce that everyone has to die at some point, but he argues that we can double our life expectancy and live healthy, active lives right up until the end.

His new book,Lifespan: Why We Age and Why We Dont Have To ($28, Atria Books), out this fall, details the cutting-edge science thats taking place in the field of longevity right now. The quick takeaway from this not-so-quick read: scientists are tossing out previous assumptions about aging, and theyve discovered several tools that you can employ right now to slow down, and in some cases, reverse the clock.

In the nineties, as a postdoc in an MIT lab, Sinclair caused a stir in the fieldwhen he discovered the mechanism that leads to aging in yeast, which offered some insight into why humans age. Using his work with yeast as a launching point, Sinclair and his lab colleagues have focused on identifying the mechanism for aging in humansand published a study in 2013 asserting that the malfunction of a family of proteins called sirtuins is the singlecause of aging. Sirtuins are responsible for repairing DNA damage and controlling overall cellular health by keeping cells on task. In other words, sirtuins tell kidney cells to act like kidney cells. If they get overwhelmed, cells start to misbehave, and we see the symptoms of aging, like organ failure or wrinkles. All of the genetic info in our cells is still there as we get older, but our body loses the ability to interpret it. This is because our body starts to run low onNAD, a molecule that activates the sirtuins: we have half as much NAD in our body when were 50 as we do at 20. Without it, the sirtuins cant do their job, and the cells in our body forget what theyre supposed to be doing.

Sinclair splits his time between the U.S.and Australia, running labs at Harvard Medical School and at the University of New South Wales. All of his research seeks to prove thataging is a problem we can solveand figure out how to stop. He argues that we can slow down the aging process, and in some cases even reverse it, by putting our body through healthy stressors that increase NAD levels and promote sirtuin activity.The role of sirtuins in aging is now fairly well accepted, but the idea that we can reactivate them (and how best to do so) is still being worked out.

Getting cold, working out hard, andgoing hungry every once in a whileall engage what Sinclair calls our bodys survival circuit, wherein sirtuins tell cells to boost their defenses in order to keep the organism (you) alive. While Sinclairs survival-circuittheory hasyet to be proven in a trial setting, theres plenty of research to suggest that exercise, cold exposure, and calorie reduction all help slow down the side effects of aging and stave off diseases associated with getting older.Fasting, in particular, has been well supported by other research: in various studies, both mice and yeast that were fed restricted diets live much longer than their well-fed cohorts. A two-year-long human experimentin the 1990s found that participants who had a restricted diet that left them hungry often had decreased blood pressure, blood-sugar levels, and cholesterol levels. Subsequent human studiesfound that decreasing calories by 12 percent slowed down biological aging based on changes in blood biomarkers.

Longevity science is a bit like the Wild West: the rules arent quite established. The research is exciting, but human clinical trials havent found anything definitive just yet.Throughout the field, theres an uncomfortable relationship between privately owned companies, researchers, and even research institutes like Harvard: Sinclair points to a biomarker test by a company called InsideTrackeras proof of his own reduced biological age, but he is also an investor in that company. He is listed as an inventor on a patent held by a NAD booster thats on the market right now, too.

While the dust settles, the bestadvice for the curious to take fromLifespan is to experiment with habitsthat are easy, free,and harmlesslike taking a brisk, cold walk and eating a lighter diet.With cold exposure, Sinclair explains, moderation is the key. He believes that you can reap benefits by simply taking a walk in the winter without a jacket. Hedoesnt prescribe an exact fasting regimenthat works best, but he doesntrecommend anything extremesimply missing a meal here and there, like skipping breakfast and having a late lunch.

Lifespan is a timely book, but its not necessarily an easy read. The science is dense, and even listening to Sinclair explain it on podcasts and during presentations doesnt help cut through all of the nerd speak. But if youre even mildly hopeful about dunking a basketball at the age of 50, or hiking the Appalachian Trail at 70, or blowing 100 candles out on your birthday cake someday, you might consider making room for Lifespan on your bookshelf. Theres enough useful information to make it worth your time.

Read more here:

This Scientist Believes Aging Is Optional - Outside Magazine

Recommendation and review posted by Alexandra Lee Anderson

Term limits would make Congress members put the country first | Letters – NJ.com

I am 81 years old and I fear that I have lived through the best years of this country. The vitriolic divide between the Republicans and Democrats is tearing this country apart and will continue to do so without a major change to our governmental structure.

There are just two actions that can alter the disastrous course on which we find ourselves: a third major political party or term limits. A third party would be a very long time coming and both parties would do everything in their collective power to prevent such an occurrence. That leaves us with term limits.

The majority of the country is opposed to the power that lobbyists exercise over this country. How did they reach this position of control? Simple. They became a significant financial asset to the long-term members of Congress who, as a result of longevity, have garnered significant influence within the government. The primary objective of most elected members of Congress is re-election. If there were some way that we could incorporate term limits into our congressional structure, our elected officials might actually put the country first.

Bob Welgos, Wharton

Its time to upgrade Newarks airport

Terminals A, B and C at Newark Liberty International Airport are in dire need of replacement to accommodate the increase in record-breaking passenger volume. I have flown in and out of each terminal, and in each one there is a shortage of restrooms. When passengers deplane, they head to the restrooms, which quickly get congested. I dont think the Port Authority of New York and New Jersey would approve adding at least three more restrooms in each lane of gate locations, especially in Terminal C, which has the largest volume of passengers.

I fly into San Diego at least twice a year, and prior to the remodeling of their terminals, you never had to search for a restroom and the airport is considerably smaller than Newarks airport.

Additional restrooms have been included in the planning even though sufficient facilities were available.

Thomas A. Kujawski, Parlin

Morris County park plan an insult

I am writing in opposition to the Morris County Parks Commissions Draft Mahlon Dickerson Reservation Forest Assessment and Stewardship Plan. This is a deal to use our common lands entrusted for the public for economic stimulus to certain contractors, not in any way benefiting the state or county agencies.

This is a direct affront and insult to the perceived green initiatives and awareness of the crisis man has created through his economic endeavor to turn nature into capital in an economy to nowhere. The fact that a private not a state or government workforce is involved says much. Using machines of overscaled necessity, rather than human labor and minimum impact under this arrangements, says it all. The repeated mistakes of tree poaching or the taking of trees not earmarked by criteria, as occurred on Sparta Mountain, showed a theft of convenience by the contractor because the incentive is lumber sales, not forest management.

Sparta Mountain is a disaster. Will Mahlon Dickerson be as well? Speak up defend our remaining public forest from private deals and further unneeded intrusions. New Jersey: Love it or leave it alone.

Nick Homyak, Lake Hiawatha

Have respect for the meat you eat

In his recent column New study is red meat for us carnivores (Oct. 31), Paul Mulshine gleefully informs us that a recent study proves there is no health-related reason for people to not eat as much red meat as they want. He also states, The real objective of many of the people who push vegetarianism on us is based not on nutrition but on other factors. And he is right about that.

One thing that avid carnivores never consider because they have been conditioned not to by the meat industry is that the tasty chunk of meat you are indulging in came from a living creature that felt emotion, fear and pain when it died for you. The least you could do is show some respect for that, instead of hiding behind the rationalization of that is what they are raised for.

Ed Miller, Hillsborough

Follow this link:

Term limits would make Congress members put the country first | Letters - NJ.com

Recommendation and review posted by Alexandra Lee Anderson

The Global Human Microbiome Market Size was Worth $ 461 Million in 2018 and is Forecasted to Reach $ 1,380 Million by 2026, at a CAGR of 17.8% During…

Human Microbiome Market

The human body serves as a host to a networked community of microbiome that outnumbers the bodys cells. The microbiome comprises all of the genetic material within a microbiota that is equivalent to the entire collection of microorganisms in a specific niche, such as the human gut or oral cavity. The interaction between the human microbiome and the immune system affects several human metabolic functions and impacts well-being. Microbiome is a viable alternative for disease research, providing a more detailed analysis of the species present in the microbiome. The study of the human microbiome is done to determine the role of these microbes in human health and diseases caused as the microbes present may be pathogenic or beneficial.

To Get The Free Sample of Global Human Microbiome Market 2019-2026 Report: https://mrsreports.com/request-sample/81103

Human Microbiome Market Dynamics

The human microbiome market growth is driven by several factors, such as massive investment in microbiome research, an increase in government funding and technological advancements.

Microbiome is attracting a lot of investment from the government as well as prominent private organizations. There are various companies and startups that are working in the field which accounts for a total of around 120. According to a report published by the Wall Street Journal, the investment in microbiome firms has increased from 2011 to 2015 by about 500%. The increase in investment and funding is due to the awareness of the uses and harms of the microbiome and how they affect the human body. Such discoveries can lead to breakthroughs in many human diseases treatments. For instance, uBiome, a company working in the microbiome segment, is developing genomic tests meant to identify and diagnose harmful microbes in the body. One of the applications of microbiome is personalized medicine, Human Longevity Inc., is putting $220 million into the of microbiome DNA to uncover disease-associated imbalances in microbial populations. This latter case is aimed at the development of personalized medicines for patients with different conditions..

Human Microbiome Market Segment AnalysisGlobal Human Microbiome Market By Product:

Global Human Microbiome Market By Technology:

Global Human Microbiome Market By Application:

Global Human Microbiome Market By End-use:

Avail The Best Offer On Global Human Microbiome Market 2019-2026: https://mrsreports.com/purchase/81103/single_user_license

Table Of Contents

1.1. Research Methodology1.2. Research Objective and Scope of the Report

2. Global Human Microbiome Market Market Definition and Overview

3. Global Human Microbiome Market Executive Summary3.1. Market Snippet by Technology3.2. Market Snippet by Technique3.3. Market Snippet by Application3.4. Market Snippet by End User3.5. Market Snippet by Region3.6. DataM CLO Scenario

4. Global Human Microbiome Market Market Dynamics4.1. Market Impacting Factors4.1.1. Drivers4.1.1.1. Huge investment in Human Microbiome research4.1.1.2. Increase in government funding4.1.1.3. Technological advancements4.1.2. Restraints4.1.2.1. Lack of skilled technicians4.1.3. Opportunity4.1.4. Impact Analysis

5. Global Human Microbiome Market Industry Analysis5.1. Porters Five Forces Analysis5.2. Supply Chain Analysis5.3. Regulatory Analysis5.4. Epidemiology

6. Global Human Microbiome Market Pipeline Analysis

7. Global Human Microbiome Market By Technology7.1. Introduction7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology7.3. Market Attractiveness Index, By Technology7.4. Shotgun7.4.1. Introduction7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)7.5. Targeted Gene7.6. RNA7.7. Whole Genome7.8. Others

8. Global Human Microbiome Market By Technique8.1. Introduction8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique8.3. Market Attractiveness Index, By Technique8.4. Synthesis By8.4.1. Introduction8.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)8.5. Synthesis By Ligation8.6. Pyro8.7. Sanger8.8. Others

9. Global Human Microbiome Market By Application9.1. Introduction9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application9.3. Market Attractiveness Index, By Application9.4. Therapeutics9.4.1. Introduction9.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-20269.5. Genetic Screening9.6. Drug Discovery9.7. Biomarker Discovery9.8. Personalized Medicines9.9. Others

10. Global Human Microbiome Market By End User10.1. Introduction10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User10.3. Market Attractiveness Index, By End User10.4. Research Institutes10.4.1. Introduction10.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-202610.5. Pharmaceutical and Biotechnology Companies10.6. Others

11. Global Human Microbiome Market By Region11.1. Introduction11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region11.3. Market Attractiveness Index, By Region11.4. North America11.4.1. Introduction11.4.2. Key Region-Specific Dynamics11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country11.4.7.1. U.S.11.4.7.2. Canada11.4.7.3. Mexico11.5. Europe11.5.1. Introduction11.5.2. Key Region-Specific Dynamics11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country11.5.7.1. Germany11.5.7.2. U.K.11.5.7.3. France11.5.7.4. Italy11.5.7.5. Spain11.5.7.6. Rest of Europe11.6. South America11.6.1. Introduction11.6.2. Key Region-Specific Dynamics11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country11.6.7.1. Brazil11.6.7.2. Argentina11.6.7.3. Rest of South America11.7. Asia-Pacific11.7.1. Introduction11.7.2. Key Region-Specific Dynamics11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country11.7.7.1. China11.7.7.2. India11.7.7.3. Japan11.7.7.4. Australia11.7.7.5. Rest of Asia Pacific11.8. Middle East and Africa11.8.1. Introduction11.8.2. Key Region-Specific Dynamics11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Market Competitive Landscape12.1. Competitive Scenario12.2. Competitor Human Microbiome Strategy Analysis12.3. Comparative Product Portfolio Analysis12.4. Market Positioning/Share Analysis12.5. Mergers and Acquisitions Analysis

13. Company Profiles13.1. BaseClear BV *13.1.1. Company Overview13.1.2. Product Portfolio and Description13.1.3. Key Highlights13.1.4. Financial Overview13.2. Clinical Microbiomics AS13.3. Locus Biosciences13.4. Human Microbiome Insights Inc.13.5. Human Microbiome Therapeutics LLC13.6. MR DNA13.7. Second Genome13.8. uBiome13.9. Molzym GmbH13.10. Zymo Research Corp.

14. Global Human Microbiome Market Premium Insights

15. Global Human Microbiome Market DataM

To Place The Pre-Order Enquiry For Global Human Microbiome Market 2019-2026: https://mrsreports.com/pre-order-enquiry/81103

We offer customization of reports according to your requirements, for example, Countries Focused, Key Players, By Application, By Type, etc. if you are interested in purchasing only a chapter or a few chapters from the report as per your current market research requirements.

About MRS Reports:

To establish a brand, a business needs to set after acquiring thorough knowledge about each and every detail of the market. Well, this may sound a bit difficult for an individual, who has to focus on multiple things in the business, to step down in the market and study every detail. Here, we come becoming a medium of insights for you. Market Research Solution researches about the verticals and analyses every detail that may relate to your requirements and your business. We bring the reports to help you with the details about your industry in a manner that suffices all your necessities and answers all your queries related to the vertical you choose to work in.

We understand your conditions of studying the gestation of technology, transformations in the economy, with the progress of the significant divisions of the market and we present to you those reports showcasing answers to all your concerns. Our researchers and analyze diversified industry verticals to prepare an exhaustive report so that you can decide the next step by analyzing its profitability. Heres a glimpse at what you can attain from partnering with us as your market research solution providers.

Contact Us:MRS ReportsAndrea Clarke,Corporate SalesPhone: +1 415 800 3648 / + 91 99212 70164Email: sales@mrsreports.comWeb: https://mrsreports.com

Here is the original post:

The Global Human Microbiome Market Size was Worth $ 461 Million in 2018 and is Forecasted to Reach $ 1,380 Million by 2026, at a CAGR of 17.8% During...

Recommendation and review posted by Alexandra Lee Anderson

Old pinyons and the climate of hope | Outdoors – Montrose Daily Press

There are 14 numbered posts on Black Canyons Warner Point Nature Trail. They are keyed to pages in a booklet that visitors pick up at the trailhead which describes the trees of the woodland along the trail. Rotted with age, we gradually replaced them this fall with new ones; anchoring them in the rocky, shallow soil.

The work takes time, except for post number 13 at one of the aged pinyon pines near the end of the trail. The marker was fairly worn, but we pulled it out with little trouble. It was the last one for that day, so we could sit under the shade of the trees spreading branches for a short break.

We dont exactly know the age of this tree, but studies in the 1940s and 1950s of tree rings from some nearby specimens, revealed ages that today approach 900 years. It started me to wonder about longevity in pinyon pines compared to that of people.

Modern medicine, in the human world, suggests that longevity might be realized by genetics, as DNA is gathered to study age-related diseases. Research related to the sequence of genes in the DNA could unlock the secrets of Illnesses like Alzheimers or Lou Gehrigs Disease (ALS).

Species, perhaps all species, have DNA (a sequence of traits) that could mean healthier or less healthy individuals. In the drought of 2002 2004, large stands of pinyon pines in New Mexico and Arizona succumbed to lack of moisture. Their weakened condition opened the door to ips beetle attack. Beetles took advantage of weakened trees, and large quantities of the trees kicked the bucket.

Back in the shade of our old pinyon, I wonder if there are traits in pinyon trees that better equip them to tolerate temperatures as they warm and conditions as they dry out. Might the gene make-up of some individual trees help them to fend off a beetle attack? Its a grand specimen; sometimes called by colleagues as the grandparent tree or the grand-pinyon tree. Over the years we have bonded with this denizen of time.

Studies have uncovered various conditions which can affect an individual pinyons chances when conditions go downhill. Soil, nutrients, rain and snow, competition from other trees, and temperature all play a part in survival success. Location is also critical. Pinyons on south facing slopes, like many on this ridge, face greater challenges than on north facing sides of hills and canyons.

A recent study of tree rings on pinyons showed that trees which have lived through wetter and drier periods, meaning they have abided through good and bad years, are more successful in getting through a warming period. On top of that, those which have survived to age 70 are more likely to live to a ripe old age than others.

An increase in heat has set the stage to a great deal of beetle kill for Douglas fir and mortality among aspen groves on the south side of Black Canyon. Overlooks and trails expose the die-off that has come about in only the past few years. Yet, after 26 years of hiking the Warner Trail, its hard not to have a concern for this grandparent pinyon that I have come to know.

I have sat with the tree as it helped me with the loss of my dad in 2006. Its fun greeting the tree at the end of an arduous hike back from Warner Point to the river. Touching its bark, smelling the piney aroma on a hot summer day, knowing that the tree is part of a community of living things similar to our own human community, and sharing the glory of old age with visitors have all been part of my relationship.

Success! An email has been sent to with a link to confirm list signup.

Error! There was an error processing your request.

The tree sits on the north facing slope of the canyon. It appears to have the usual advantages to survive. Its hard not knowing if it might have a genetic advantage to live through increasing heat and lower moisture in the years ahead.

People who look to the future with promise often find additional years added to their life, whether its in their genes or not. It seems that other factors can contribute to longevity in both humans and plants.

Still, pinyon trees, like the grand pinyon inspire hope. Not an uninformed, ingenuous hope. This is a hope that gives flight to love of trees and woodlands. And in that regard the longevity question is less important than the pull given by that great old tree to have a heart open to the land.

Paul Zaenger has been a supervisory park ranger at Black Canyon of the Gunnison National Park since 1993. Other park assignments include Mount Rushmore National Memorial and Glen Canyon National Recreation Area.

See the original post:

Old pinyons and the climate of hope | Outdoors - Montrose Daily Press

Recommendation and review posted by Alexandra Lee Anderson

New "Monsterpocalypse" releases: Ulgoth, Apes, and Robots, Oh My! – Bleeding Cool News

Monsterpocalypse from Privateer Press is unlike any other miniature game on the market. Players assemble and paint teams of giant monsters, then bring those monsters together to fight it out over a model city. Monsterpocalypse takes everything you love about Godzilla, King Kong, Ultraman, and Power Rangers and puts it all into the palm of your hand.

The latest Monsterpocalypse releases had a lot to offer just about anyone who loves giant monsters! Im going to start with the latest Kingdom of the Apes releases, since, well, giant fighting apes.

Thought to have emerged from somewhere within the harshest and most inaccessible peaks of the Himalayas, White Dajan is a ferocious giant ape that has emerged to confront Earths would-be despoilers. Possessing the power to summon winters ferocity, White Dajan is noted for his rage and unbridled violence even among the Empire of the Apes. He seems to have a particular hatred for buildings and crowded cities, seeking to level such structures whenever his anger is provoked. This makes him a perilous guardian, though he has also shown affection for humanity and a willingness to fight alongside them. Considering the foes Earth faces, a few toppled buildings are considered an acceptable price to pay to appease this formidable ally.

White Dajan also gets a little reinforcement from these crazy ape bombers, who appear to be riding bombs into battle!

Though the most gargantuan of the great apes might be mistaken for unthinking beasts, their intelligence is demonstrated by their ground forces, who possess borrowed technology that they utilize with uncanny sophistication. Ape bombers soar through the air on jury-rigged portable jet engines, capable of dropping high-yield explosives with considerable accuracy. And command apes have been witnessed making use of radio communication devices to orchestrate attacks, despite the fact that the language they employ seems like nothing but gibberish to human ears.

The Lords of Cthul have a new beastie, a nasty looking monster called Ulgoth:

An otherworldly embodiment of toxicity and pain, Ulgoths very blood destroys what he does not directly assault, and the world itself shudders in his passage. Unlike some other Lords of Cthul, it is difficult to determine if Ulgoth is even intelligent, so far as humanity is concerned, as it seems almost more a force of supernatural destruction and transformation. Wherever it treads, the world is changed around it, and some scientists have theorized Ulgoth might be akin to a sinister terraforming device, one bent on changing the very nature of the Earth into an environment more amenable to creatures of Cthul. It is also responsible for hastening the proliferation of lesser horrors from their reality, spawning and summoning such beings with a frequency that defies reason.

Ulgoth is not the type of monster that will be shown up by some damned dirty ape, so it brought its own reinforcements into battle:

It is difficult for even the brightest minds of humanity to understand the fiendish creatures of the Lords of Cthul. Snatchers are among the most feared of their lesser minions, bloated hovering creatures capable of seizing hapless victims and transforming them into a similar biomass of Cthulians. Against such a fate, some might consider the alternative of being torn apart by a swooping Hellion to be preferable. Hellions are batlike hunters capable of swift movement and similarly swift foe neutralization.

Finally, for those of you who like your giant, stomping Monsterpocalypse action in a mechanized form, there is Gorghadratron, who fights for whoever can afford its massive price tag:

Nothing demonstrates the military manufacturing capabilities of UberCorp International better than its gigantic weaponized hardware platforms, each customized to monstrous configurations. Gorghadratron brings the raw obliterating power of the so-called Planet Eaters to anyone with sufficient funds to commit to an exclusive purchasers license. Built with innovative polymers and alloys derived from recovered xenoexobiological materials, Gorghadratron is as durable as it is lethal, with longevity assured by the recommended 10-year UberCorp maintenance contract, purchased separately. UberCorp cannot be held responsible for any collateral damage incurred by overloading Gorghadratrons reactors.

Leigh George Kade is a writer, illustrator, and sculptor who lives in Salt Lake City with his wife and two small Skrulls. Leigh has also been a panelist on the wildly popular Geek Show Podcast since 2008. He has been an Entertainment Writer for Bleeding Cool since 2018.

Go here to read the rest:

New "Monsterpocalypse" releases: Ulgoth, Apes, and Robots, Oh My! - Bleeding Cool News

Recommendation and review posted by Alexandra Lee Anderson

The benefits of intermittent fasting – Starjournalnow

By Wendy M. HenrichsBoard Certified Chiropractic Pediatrician and Nutrition Counselor

Is your diet in need of a reboot before the holidays? Remember that your diet is how and what you eat, not something that you do for a short period of time to lose weight. There are several popular diet patterns today, including Keto, Paleo, Gluten Free, Low Carb, High Protein, Whole 30, and Mediterranean. The number one diet pattern in 2018 was Intermittent Fasting. This article will explore intermittent fasting and its benefits. If you are looking for ways to manage your weight, decrease inflammation and pain, lower your blood pressure, lower your total cholesterol, decrease your risk for heart disease and diabetes along with having more energy and longevity then intermittent fasting could be for you.

Fasting originated in ancient evolution and healing tradition across millennia. It has been shown to support overall metabolic health. It supports cellular cleanup which leads to cellular regeneration and an increase in circulating stem cells (i.e. younger cells). It impacts genetic markers associated with an increase in human longevity and health span.

Fasting is not a fad. In Obesity 2019, those practicing time-restricted eating within a six-hour period and fasting for 18 hours improved fat-burning and lowered levels of the hungry hormone ghrelin, as compared to those who ate exact same meals in 12-hour period. Eating only during limited hours can improve weight management, increase longevity, and improve our immune systems ability to fight disease. Mt. Sinai researchers published a study (Cell, Aug. 22, 2019) showing that fasting reduces inflammation and improves chronic inflammatory diseases without affecting the immune systems response to acute infections. Intermittent fasting is known to improve sensitivity to blood glucose, lower blood glucose, protect against fatty liver, and lower pancreatic fat.

There are several approaches to intermittent fasting but, in my opinion, a 12-16 hour fasting period that includes breakfast and eating your last meal before 6 p.m. is doable for the average person with a multitude of benefits. A study published in Nutrients 2019 compared the effects of eating a high fat, high sugar diet (the Standard American Diet-SAD) to a 12-16-hour intermittent fasting diet. Eating more than six meals and snacks daily while skipping breakfast, eating high fat and high sugar, and eating the last meal later at night with a reduced fasting period causes increased hunger, inflammation and total cholesterol, and a decrease in insulin sensitivity. Just skipping breakfast leads to increased LDLs, increased body fat, increased weight and an increased incidence of diabetes. Eating breakfast and eating your last meal before 6pm with a fasting period between 12-16 hours has many positive effects such as decreased hunger, decreased inflammation (leads to decreased pain), decreased total cholesterol and increased insulin sensitivity. There were also decreases in LDLs, blood pressure, body weight, body fat and a decreased risk of diabetes and heart disease. These are some very compelling reasons to consider intermittent fasting.

Some things to keep in mind if you are considering intermittent fasting: Eat Breakfast: Breakfast is the most important meal of the day. It ignites your metabolism and your brain. Breakfast should include protein, healthy fats (avocado, grass-fed organic butter, salmon, omega 3 eggs, nuts or seeds), fruit or vegetables. Skipping breakfast leads to increases in body weight, body fat, LDLs and risk of diabetes. Eat Dinner/Supper before 6 p.m. (if possible): Eating later at night leads to increases in fat deposition, blood pressure, cholesterol and increased risk of diabetes and heart disease. I suggest brushing your teeth after supper which helps prevent the evening noshing. Your dinner should include four ounces of lean protein (organic chicken, grass fed beef, wild game, wild caught fish, or legumes) paired with one to two cups of steamed vegetables and/or leafy greens. If you must have starch, limit it to a half-cup serving. Eat three meals a day with two small snacks (if needed) that include protein, good fats, veggies and/or fruits. Fast for 12-16 hours between supper and breakfast: This improves your ability to burn stored fat, which amps up your metabolism. Eat whole foods that do not come from boxes or packages. That is, eat mostly plant derived food like fresh or frozen fruits and vegetables plus lean protein sources such as eggs, organic chicken, grass fed beef, wild game, wild caught fish, legumes and nuts. Eat organic foods as much as possible. Visit http://www.ewg.org for the dirty dozen and clean 15 as a guide. Eat good fats from grass fed butter, olive oil, coconut oil, avocado oil and grape seed oil. Drink half of your body weight in ounces of water daily. Try for eight ounces of water per hour throughout your waking hours. Avoid trans fats, hydrogenated and partially hydrogenated oils/fats.

Intermittent fasting was used by our ancestors, sometimes out of necessity. It is a way to lower your blood pressure, lower your cholesterol and LDLs, decrease your risk for diabetes and heart disease along with long term weight management while increasing energy and longevity. Consider intermittent fasting as a means to not only live longer but get more life out of your years.

Dr. Wendy Henrichs is a board certified chiropractor and nutrition counselor at Timber Land Chiropractic in Rhinelander. For a complimentary chiropractic, nutrition or lifestyle counseling consultation, visit TimberlandChiropractic.com, Facebook, or call 715-362-4852.

See the original post:

The benefits of intermittent fasting - Starjournalnow

Recommendation and review posted by Alexandra Lee Anderson

What bamboo forests do for nature and human well-being – Forests News, Center for International Forestry Research

Kiran Paudyal is an ecosystems services specialist at Forest Action Nepal. Chun Bahadur Gurung, is a development communication specialist and Ph.D. candidate at Tribhuvan University in Nepal.

Bamboo, which belongs to the grass family, is one of the fastest growing species of the plant kingdom. Its herculean attributes are not at first obvious when encountered in the forest. Although its hollow stems that bend in the wind may make it appear weak, its provision of a wide variety of ecosystem services defined as the direct and indirect contributions of ecosystems to human well-being, makes this an invaluable plant.

Found in tropical and alpine climatic zones of Africa, Asia, Central and South America, scientists have so far recorded more than 1,600 bamboo species, which combined cover more than 31 million hectares of land.

With myriad potential uses, bamboo is an essential material for people living in poverty in developing countries. It is widely used as a raw material in industry, in handicrafts, its fibers are used to weave clothes and make paper, and its shoots and sprouts are used for food.

It may be no surprise then, that bamboo features heavily in cultural traditions. In Indonesia, it is used in ceremonies and in the construction of such instruments as the Balinese rindik. In China, its symbolism of modest character and longevity is heralded; in rural Nepal, babies sleep in beautiful bamboo cradles and the dead are buried in bamboo coffins.

From floods to good fortune in Nepal

Nepal a landlocked country is blessed with bamboo diversity. The country has more than 53 species covering an estimated area of 63,000 hectares of land.

Nepal has a tale to tell, a story of 70 households from Gauringar village, Chitwan, in the center of the country. In 2010, incessant rain caused flash floods. Homes and buildings near the Rui river in Gauringar were destroyed. When the river banks were washed away, tons of silt and sand flooded the land, rendering it infertile.

The resilient residents worked hard to reverse their fortunes: in their efforts, they planted 10,000 native bamboo seedlings. In less than a decade, the flood-ravaged land turned into a beautiful bamboo forest. Some 700 hectares of land were rehabilitated, allowing local communities to enjoy bamboo shoots for food and all of the benefits the bamboo forest provides. The new forest has even become instrumental in mitigating human-wildlife conflict, as Gauringar sits in the buffer zone of Chitwan National Park, home to the rhino, sloth bear, tiger, elephant, wild boar and leopard.

Bamboo for water and energy in Indonesia

Across the Indonesian archipelago, bamboo can be found in 30 provinces, covering 2.1 million hectares of land. By selling bamboo shoots, a farmer on Java can earn $420700 per hectare, while others have recognized it for its incredible restoration properties. Scientist Yusuf Samsudin at the Center for International Forestry Research (CIFOR) reports how payments for environmental services (PES) have been awarded to communities living up-stream of Mount Batur and its lake in Bali, where the main water source for coastal communities flows. While many trees store around 35 to 40 percent of rainfall, bamboo can store up to 90 percent of rainfall.

Bamboo can provide sustainable supplies of biomass for energy productionwithout compromising food security or unduly affecting the wider landscape. One of CIFORs partners Clean Power Indonesia successfully developed a community-based power plant that uses biomass from bamboo in rural Indonesia. CIFOR Senior Scientist Himlal Baral says that CIFOR and partners are currently looking for opportunities to scale this up in several locations in Indonesia.

Untapped green good in Ethiopia

In Ethiopia, two main bamboo species (Arundinaria alpine and Oxytenanthera abyssinica) grow naturally in six regions on a million hectares of land, making up 8.2 percent of the total forest area of the country.

However, bamboo was close to extinction in natural forests due to agriculture-related deforestation and forest degradation, and demand for fuelwood and timber in the villages. In the 1990s, more than 100 innovative smallholders planted savanna bamboo within agroforestry systems using a rhizome offset method from the natural forest, developing bamboo forests in the villages for multiple benefits.

Although bamboo coverage has been high in Ethiopia in recent years, uses have been traditional, and its full export market potential has yet to be realized.

Because bamboo is a fast-growing species and adapts to harsh environments, people in Ethiopia are likely to pay more attention to it for rehabilitating degraded areas.

The missing link an ecosystem services framework built from bamboo

According to Sisay Nune et al. (2013) the capacity to provide regulating services such as soil conservation, environmental rehabilitation and carbon sequestration of forestland and other forest types, were assumed to be 99 and 93 percent respectively as compared with bare land. Thanks to a complex network of rhizome-root systems underground.

A recent study has shown that the ecosystem services a bambooforest can provide support natural, plantations, grasslands, and farmlands. Additionally, bamboo forests have proven more effective in slope stabilization and soil erosion control compared to other land use practices such as forests and grasslands.

It has an incredible ability to restore land, making it an important contributor in reaching such global restoration agreements as the Bonn Challenge and the New York Declaration on Forests. Experts engaged in bamboo research agree that a good framework is key to improve assessment of bamboo ecosystem services and to further strengthen bamboo forests for landscape restoration globally. During this research, the experts agreed that the lack of an appropriate framework, tools and methods means that the true ecosystem services of bamboo forests have not been properly assessed.

The best ecosystem service assessment framework accounts for the significance of bamboo forests to people and policymakers. Recently, Kiran Paudyal et al. (2019) designed a framework and tested it in Nepal, Indonesia and Ethiopia.

Contributions received from local communities and government further refined it, which facilitates limited resources while offering new opportunities to connect bamboo forests with ecosystem service markets from local to global scales such as PES including payment for carbon through REDD+ programs. The recently developed framework can now be replicated in other parts of the world.

Scientists are deeply concerned that the benefits of bamboo often go unnoticed. In view of the plants important but under-appreciated benefits, Paudyal, a bamboo expert said: Bamboo recharges groundwater and it significantly absorbs carbon, but it is hardly acknowledged.

An ecosystem framework can help significantly in the promotion of bamboo forests through effective management. Case studies conducted in three countries with different contexts confirmed that bamboo forests become increasingly important, and the study also validates that bamboos benefits have been found quite common globally.

Bamboo forests in different countries and context, have proven to be the best option for both landscape restoration and the supply of various ecosystem services. These forests supply more ecosystem services than any other type of planted forests. Restoration of degraded and abandoned land with bamboo could be an effective solution to cope with poverty, hunger and climate change in many parts of the world especially in developing countries.

This research was funded by CIFOR as part of the CGIAR Research Program on Forests, Trees and Agroforestry and the International Bamboo and Rattan Organisation (INBAR), China.

(Visited 1 times, 1 visits today)

Continue reading here:

What bamboo forests do for nature and human well-being - Forests News, Center for International Forestry Research

Recommendation and review posted by Alexandra Lee Anderson


Page 1123